CONMED Corporation (CNMD) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$37.32
Price Target
$78.00
Target Range
$61.00 — $95.00
Analyst Rating
Hold
Forward P/E8.5x
Trailing P/E24.7x
Forward PEG0.23
Implied Growth+144.2%
Median Target$78.00
Analyst Spread43.6%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$61
+63.5%
Consensus
$78
+109.0%
Bull Case
$95
+154.6%
Valuation Model TargetsConfidence: 52/100
Bear$11
Base$69
Bull$42
CNMD Price Target Analysis
Updated May 7, 2026As of May 7, 2026, CONMED Corporation (CNMD) has a Wall Street consensus price target of $78.00, based on estimates from 21 covering analysts. With the stock currently trading at $37.32, this represents a potential upside of +109.0%. The company has a market capitalization of $1.15B.
Analyst price targets range from a low of $61.00 to a high of $95.00, representing a 44% spread in expectations. The median target of $78.00 aligns closely with the consensus average.
The current analyst consensus rating is Hold, with 7 analysts rating the stock as a Buy or Strong Buy,14 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, CNMD trades at a trailing P/E of 24.7x and forward P/E of 8.5x. The forward PEG ratio of 0.23 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +144.2% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $69.08, with bear and bull scenarios of $10.73 and $42.20 respectively. Model confidence stands at 52/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+39.4%
Avg Forward P/E59.7x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 HOLXHologic, Inc. | $17.0B | $76.01 | $79.00 | +3.9% | Hold | 17.2x | 42 |
 ATRCAtriCure, Inc. | $1.4B | $28.01 | $50.67 | +80.9% | Buy | 373.5x | 19 |
 NVCRNovoCure Limited | $1.9B | $16.50 | $33.50 | +103.1% | Buy | — | 15 |
 MMSIMerit Medical Systems, Inc. | $3.7B | $61.63 | $95.00 | +54.1% | Buy | 15.3x | 13 |
 LMATLeMaitre Vascular, Inc. | $2.5B | $110.22 | $101.50 | -7.9% | Buy | 38.0x | 20 |
 SYKStryker Corporation | $112.0B | $292.33 | $403.69 | +38.1% | Buy | 19.5x | 50 |
 ZBHZimmer Biomet Holdings, Inc. | $16.2B | $82.83 | $97.90 | +18.2% | Hold | 9.8x | 42 |
 BSXBoston Scientific Corporation | $83.2B | $56.00 | $91.33 | +63.1% | Buy | 16.6x | 43 |
 EWEdwards Lifesciences Corporation | $48.0B | $83.20 | $96.53 | +16.0% | Buy | 27.7x | 48 |
 GMEDGlobus Medical, Inc. | $12.1B | $89.22 | $110.67 | +24.0% | Buy | 20.0x | 36 |
Upside Potential Comparison
NVCRATRCBSXMMSISYKGMEDZBHEWSee CNMD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CNMD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CNMD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCNMD — Frequently Asked Questions
Quick answers to the most common questions about buying CNMD stock.
What is the CNMD stock price target for 2026?
The consensus Wall Street price target for CNMD is $78, representing 109.0% upside from the current price of $37.32. With 21 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is CNMD a buy, sell, or hold?
CNMD has a consensus rating of "Hold" based on 21 Wall Street analysts. The rating breakdown is mixed, with 14 Hold ratings making up the largest segment. The consensus 12-month price target of $78 implies 109.0% upside from current levels.
Is CNMD stock overvalued or undervalued?
With a forward P/E of 8.5336x, CNMD trades at a relatively low valuation. The consensus target of $78 implies 109.0% appreciation, suggesting meaningful undervaluation.
How high can CNMD stock go?
The most bullish Wall Street analyst has a price target of $95 for CNMD, while the most conservative target is $61. The consensus of $78 represents the median expectation. Our quantitative valuation model projects a bull case target of $42 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover CNMD stock?
CNMD is well covered by analysts, with 21 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 14 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the CNMD stock forecast?
The 12-month CNMD stock forecast based on 21 Wall Street analysts shows a consensus price target of $78, with estimates ranging from $61 (bear case) to $95 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $69, with bear/bull scenarios of $11/$42.
What is CNMD's fair value based on fundamentals?
Our quantitative valuation model calculates CNMD's fair value at $69 (base case), with a bear case of $11 and bull case of $42. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 52/100.
What is CNMD's forward P/E ratio?
CNMD trades at a forward P/E ratio of 8.5x based on next-twelve-months earnings estimates compared to a trailing P/E of 24.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy CNMD stock?
Wall Street analysts are very optimistic on CNMD, with a "Hold" consensus rating and $78 price target (109.0% upside). 7 of 21 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do CNMD price targets vary so much?
CNMD analyst price targets range from $61 to $95, a 44% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $78 consensus represents the middle ground. Our model's $11-$42 range provides an independent fundamental perspective.